minoxidil 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
vasodilators	1814	38304-91-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: minoxidil loniten rogaine	A potent direct-acting peripheral vasodilator (VASODILATOR AGENTS) that reduces peripheral resistance and produces a fall in BLOOD PRESSURE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p371) Molecular weight: 209.25 Formula: C9H15N5O CLOGP: 0.38 LIPINSKI: 0 HAC: 6 HDO: 2 TPSA: 93.63 ALOGS: -1.02 ROTB: 1 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

minoxidil
loniten
rogaine

A potent direct-acting peripheral vasodilator (VASODILATOR AGENTS) that reduces peripheral resistance and produces a fall in BLOOD PRESSURE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p371)

Molecular weight: 209.25
Formula: C9H15N5O
CLOGP: 0.38
LIPINSKI: 0
HAC: 6
HDO: 2
TPSA: 93.63
ALOGS: -1.02
ROTB: 1

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
20	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	2.20 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	10 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	6.83 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	95 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.90 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	11.50 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	1 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.50 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Oct. 18, 1979	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hypertrichosis	304.15	19.50	54	3891	1100	63483977
Product formulation issue	165.27	19.50	29	3916	549	63484528
Hair texture abnormal	54.13	19.50	17	3928	4226	63480851
Hair growth abnormal	51.13	19.50	15	3930	2966	63482111
Application site pruritus	46.84	19.50	15	3930	3969	63481108
Hair colour changes	41.86	19.50	13	3932	3114	63481963
Product use in unapproved indication	37.97	19.50	51	3894	179029	63306048
Wrong patient received product	37.38	19.50	11	3934	2196	63482881
Application site exfoliation	37.22	19.50	8	3937	446	63484631
Injection site alopecia	34.16	19.50	5	3940	27	63485050
Off label use	33.86	19.50	105	3840	674357	62810720
Product preparation error	33.37	19.50	13	3932	6079	63478998
Dermatitis contact	32.03	19.50	15	3930	10993	63474084
Cardiac hypertrophy	30.58	19.50	8	3937	1037	63484040
Drug ineffective for unapproved indication	29.35	19.50	21	3924	34042	63451035
Tachycardia	28.68	19.50	36	3909	118120	63366957
Dermatitis	25.91	19.50	15	3930	16943	63468134
Arrhythmia	25.07	19.50	20	3925	38120	63446957
Product use issue	24.78	19.50	47	3898	220473	63264604
Dandruff	23.77	19.50	5	3940	251	63484826
Vanishing bile duct syndrome	23.34	19.50	6	3939	726	63484351
Application site pain	23.17	19.50	9	3936	4173	63480904
Product administration error	22.08	19.50	15	3930	22382	63462695
Hypertensive crisis	21.98	19.50	13	3932	15273	63469804
Glomerulonephritis acute	21.84	19.50	4	3941	97	63484980
Hypertension	20.40	19.50	50	3895	279253	63205824
Pericardial effusion	20.26	19.50	16	3929	30042	63455035
Occupational asthma	20.00	19.50	4	3941	156	63484921
Hirsutism	19.52	19.50	6	3939	1389	63483688

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hypertrichosis	348.56	20.23	60	5580	353	34950938
Product formulation issue	284.24	20.23	53	5587	517	34950774
Pericardial effusion	161.57	20.23	79	5561	24583	34926708
Product label on wrong product	51.56	20.23	8	5632	21	34951270
Renal cyst haemorrhage	45.20	20.23	12	5628	627	34950664
Rectal prolapse	43.34	20.23	11	5629	481	34950810
Ceruloplasmin increased	40.51	20.23	6	5634	10	34951281
Nephrogenic systemic fibrosis	39.26	20.23	17	5623	3988	34947303
Blood copper increased	37.84	20.23	6	5634	19	34951272
Intraductal papillary mucinous neoplasm	37.62	20.23	10	5630	525	34950766
Swelling of eyelid	34.48	20.23	11	5629	1100	34950191
Oedema peripheral	33.34	20.23	65	5575	119747	34831544
Vascular anastomotic haemorrhage	33.27	20.23	8	5632	279	34951012
Aortic dilatation	31.97	20.23	11	5629	1390	34949901
Vascular compression	31.12	20.23	8	5632	368	34950923
Delayed graft function	30.51	20.23	12	5628	2209	34949082
Hypervolaemia	29.77	20.23	25	5615	19684	34931607
Scrotal oedema	29.13	20.23	11	5629	1815	34949476
Abdominal wall haemorrhage	29.02	20.23	8	5632	482	34950809
Carotid arteriosclerosis	28.94	20.23	11	5629	1847	34949444
Cardiac tamponade	28.93	20.23	15	5625	5251	34946040
Perineal cyst	28.55	20.23	7	5633	265	34951026
Product monitoring error	28.53	20.23	14	5626	4367	34946924
Dermatitis contact	28.19	20.23	13	5627	3533	34947758
Cardiac failure congestive	27.95	20.23	49	5591	83221	34868070
Left ventricular hypertrophy	27.89	20.23	17	5623	8113	34943178
Dizziness	27.08	20.23	87	5553	218434	34732857
Hyperparathyroidism secondary	27.03	20.23	10	5630	1558	34949733
Vena cava injury	27.00	20.23	7	5633	333	34950958
Renal artery stenosis	26.84	20.23	11	5629	2250	34949041
Erectile dysfunction	26.77	20.23	24	5616	20613	34930678
Hypertensive crisis	26.73	20.23	17	5623	8734	34942557
Complications of transplanted kidney	24.95	20.23	13	5627	4596	34946695
Libido decreased	24.72	20.23	13	5627	4683	34946608
Myocardial necrosis	23.99	20.23	6	5634	247	34951044
Blood 25-hydroxycholecalciferol decreased	23.62	20.23	6	5634	263	34951028
Spinal stenosis	23.32	20.23	13	5627	5256	34946035
Mean cell volume increased	23.28	20.23	11	5629	3158	34948133
Intervertebral disc space narrowing	22.98	20.23	8	5632	1047	34950244
Restless legs syndrome	22.51	20.23	15	5625	8339	34942952
Actinic keratosis	22.23	20.23	12	5628	4555	34946736
Application site pain	21.69	20.23	9	5631	1899	34949392
Hypertension	21.30	20.23	59	5581	136384	34814907
SARS-CoV-2 antibody test positive	20.92	20.23	6	5634	418	34950873
Diverticulum intestinal	20.80	20.23	11	5629	4010	34947281
Skin induration	20.65	20.23	9	5631	2142	34949149
Hepatosplenomegaly	20.42	20.23	11	5629	4158	34947133
Chorioretinopathy	20.27	20.23	8	5632	1485	34949806

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hypertrichosis	641.27	19.09	111	7821	1171	79735285
Product formulation issue	424.49	19.09	75	7857	897	79735559
Pericardial effusion	159.21	19.09	82	7850	46155	79690301
Dermatitis contact	54.28	19.09	25	7907	11008	79725448
Product label on wrong product	53.93	19.09	8	7924	27	79736429
Renal cyst haemorrhage	50.01	19.09	12	7920	680	79735776
Hypertensive crisis	44.50	19.09	27	7905	20743	79715713
Product monitoring error	43.25	19.09	20	7912	8886	79727570
Ceruloplasmin increased	42.38	19.09	6	7926	13	79736443
Cardiac failure congestive	39.47	19.09	59	7873	142343	79594113
Blood copper increased	39.26	19.09	6	7926	26	79736430
Intraductal papillary mucinous neoplasm	38.45	19.09	10	7922	788	79735668
Hair growth abnormal	37.32	19.09	13	7919	2771	79733685
Vascular anastomotic haemorrhage	37.12	19.09	8	7924	279	79736177
Application site pruritus	36.92	19.09	14	7918	3796	79732660
Left ventricular hypertrophy	36.04	19.09	19	7913	11172	79725284
Scrotal oedema	35.86	19.09	11	7921	1574	79734882
Hypertension	34.66	19.09	91	7841	330901	79405555
Aortic dilatation	34.41	19.09	11	7921	1801	79734655
Rectal prolapse	32.43	19.09	11	7921	2167	79734289
Oedema peripheral	32.37	19.09	75	7857	252213	79484243
Application site exfoliation	32.15	19.09	8	7924	528	79735928
Perineal cyst	32.00	19.09	7	7925	262	79736194
Vascular compression	31.60	19.09	8	7924	566	79735890
Cardiac hypertrophy	31.39	19.09	10	7922	1620	79734836
Renal artery stenosis	30.90	19.09	12	7920	3470	79732986
Delayed graft function	30.81	19.09	12	7920	3495	79732961
Hair texture abnormal	30.73	19.09	12	7920	3522	79732934
Carotid arteriosclerosis	30.29	19.09	11	7921	2645	79733811
Hyperparathyroidism secondary	30.27	19.09	11	7921	2649	79733807
Vena cava injury	30.12	19.09	7	7925	345	79736111
Abdominal wall haemorrhage	30.09	19.09	8	7924	686	79735770
Complications of transplanted kidney	29.99	19.09	14	7918	6352	79730104
Swelling of eyelid	29.85	19.09	12	7920	3799	79732657
Occupational asthma	29.20	19.09	4	7928	6	79736450
Hypotension	29.10	19.09	103	7829	440214	79296242
Hypervolaemia	29.09	19.09	28	7904	42662	79693794
Product preparation error	28.10	19.09	13	7919	5780	79730676
Cardiac tamponade	27.76	19.09	15	7917	9261	79727195
Actinic keratosis	27.57	19.09	13	7919	6029	79730427
Application site pain	27.30	19.09	12	7920	4735	79731721
Tachycardia	26.33	19.09	56	7876	177712	79558744
Nephrogenic systemic fibrosis	24.32	19.09	12	7920	6148	79730308
Blood 25-hydroxycholecalciferol decreased	24.30	19.09	6	7926	383	79736073
Dandruff	24.15	19.09	6	7926	393	79736063
Electrocardiogram ST segment depression	23.82	19.09	11	7921	4867	79731589
SARS-CoV-2 antibody test positive	23.58	19.09	6	7926	433	79736023
Intervertebral disc space narrowing	22.87	19.09	8	7924	1727	79734729
Myocardial necrosis	22.80	19.09	6	7926	495	79735961
Hepatosplenomegaly	21.54	19.09	11	7921	6058	79730398
Mean cell volume increased	21.23	19.09	11	7921	6242	79730214
Kidney transplant rejection	21.13	19.09	13	7919	10233	79726223
Chorioretinopathy	20.91	19.09	8	7924	2223	79734233
Product prescribing error	20.89	19.09	24	7908	44789	79691667
Chronic kidney disease	20.63	19.09	29	7903	66125	79670331
Face oedema	20.21	19.09	19	7913	28117	79708339
Palpitations	20.04	19.09	41	7891	126569	79609887
Blood potassium increased	19.57	19.09	19	7913	29256	79707200
Restless legs syndrome	19.29	19.09	16	7916	20076	79716380
Hypertensive emergency	19.19	19.09	8	7924	2777	79733679

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C02DC01	CARDIOVASCULAR SYSTEM ANTIHYPERTENSIVES ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON Pyrimidine derivatives
ATC	D11AX01	DERMATOLOGICALS OTHER DERMATOLOGICAL PREPARATIONS OTHER DERMATOLOGICAL PREPARATIONS Other dermatologicals
FDA PE	N0000175379	Arteriolar Vasodilation
FDA EPC	N0000175564	Arteriolar Vasodilator
MeSH PA	D000959	Antihypertensive Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D014665	Vasodilator Agents
CHEBI has role	CHEBI:35620	vasodilator agents
CHEBI has role	CHEBI:35674	antihypertensive drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypertensive disorder	indication	38341003	DOID:10763
Alopecia	indication	56317004	DOID:987
Pericarditis	contraindication	3238004	DOID:1787
Myocardial infarction	contraindication	22298006	DOID:5844
Orthostatic hypotension	contraindication	28651003
Cardiac tamponade	contraindication	35304003	DOID:115
Chronic heart failure	contraindication	48447003
Disorder of cardiovascular system	contraindication	49601007	DOID:1287
Cerebrovascular disease	contraindication	62914000	DOID:6713
Kidney disease	contraindication	90708001	DOID:557
Angina pectoris	contraindication	194828000
Cerebrovascular accident	contraindication	230690007
Pheochromocytoma	contraindication	302835009
Pericardial effusion	contraindication	373945007	DOID:118
Dermatosis of scalp	contraindication	402694007	DOID:3136

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.35	Basic
pKa2	2.62	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Sulfonylurea receptor 2, Kir6.2	Ion channel	O60706 Q14654	ABCC9_HUMAN KCJ11_HUMAN	OPENER				CHEMBL	SCIENTIFIC LITERATURE
ATP-sensitive inward rectifier potassium channel 1	Ion channel	P48048	KCNJ1_HUMAN		IC50	6.97		WOMBAT-PK

External reference:

ID	Source
4018077	VUID
N0000146416	NUI
D00418	KEGG_DRUG
4018077	VANDF
C0026196	UMLSCUI
CHEBI:6942	CHEBI
MXD	PDB_CHEM_ID
CHEMBL802	ChEMBL_ID
DB00350	DRUGBANK_ID
D008914	MESH_DESCRIPTOR_UI
4201	PUBCHEM_CID
4254	IUPHAR_LIGAND_ID
2987	INN_ID
5965120SH1	UNII
202706	RXNORM
1335	MMSL
2064	MMSL
5119	MMSL
7147	MMSL
d00135	MMSL
000637	NDDF
387272001	SNOMEDCT_US
49577002	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
good sense hair regrowth treatment	HUMAN OTC DRUG LABEL	1	0113-0294	AEROSOL, FOAM	5 g	TOPICAL	ANDA	16 sections
good sense hair regrowth treatment	HUMAN OTC DRUG LABEL	1	0113-0294	AEROSOL, FOAM	5 g	TOPICAL	ANDA	16 sections
Good Sense Hair Regrowth Treatmentfor Men	HUMAN OTC DRUG LABEL	1	0113-0798	SOLUTION	3 g	TOPICAL	ANDA	16 sections
Good Sense Hair Regrowth Treatment	HUMAN OTC DRUG LABEL	1	0113-1032	SOLUTION	5 g	TOPICAL	ANDA	16 sections
Good Sense Hair Regrowth Treatment	HUMAN OTC DRUG LABEL	1	0113-1032	SOLUTION	5 g	TOPICAL	ANDA	16 sections
Good Sense Hair Regrowth Treatment	HUMAN OTC DRUG LABEL	1	0113-1129	AEROSOL, FOAM	50 mg	TOPICAL	ANDA	16 sections
basic care hair regrowth treatment	HUMAN OTC DRUG LABEL	1	0113-7032	SOLUTION	5 g	TOPICAL	ANDA	16 sections
basic care hair regrowth treatment	HUMAN OTC DRUG LABEL	1	0113-7129	AEROSOL, FOAM	50 mg	TOPICAL	ANDA	16 sections
basic care hair regrowth treatment	HUMAN OTC DRUG LABEL	1	0113-7202	SOLUTION	2 g	TOPICAL	ANDA	16 sections
basic care hair regrowth treatment	HUMAN OTC DRUG LABEL	1	0113-7294	AEROSOL, FOAM	5 g	TOPICAL	ANDA	16 sections
Basic Care Hair Regrowth	HUMAN OTC DRUG LABEL	1	0113-7798	SOLUTION	3 g	TOPICAL	ANDA	16 sections
hair regrowth treatment	HUMAN OTC DRUG LABEL	1	0363-0032	SOLUTION	5 g	TOPICAL	ANDA	16 sections
hair regrowth treatment	HUMAN OTC DRUG LABEL	1	0363-0032	SOLUTION	5 g	TOPICAL	ANDA	16 sections
hair regrowth treatment	HUMAN OTC DRUG LABEL	1	0363-0703	SOLUTION	2 g	TOPICAL	ANDA	16 sections
hair regrowth treatment	HUMAN OTC DRUG LABEL	1	0363-1129	AEROSOL, FOAM	50 mg	TOPICAL	ANDA	16 sections
Solution	HUMAN OTC DRUG LABEL	1	0363-2173	SOLUTION	0.02 g	TOPICAL	ANDA	13 sections
Solution	HUMAN OTC DRUG LABEL	1	0363-2173	SOLUTION	0.02 g	TOPICAL	ANDA	13 sections
hair regrowth treatment	HUMAN OTC DRUG LABEL	1	0363-2294	AEROSOL, FOAM	5 g	TOPICAL	ANDA	16 sections
hair regrowth treatment	HUMAN OTC DRUG LABEL	1	0363-2294	AEROSOL, FOAM	5 g	TOPICAL	ANDA	16 sections
hair regrowth treatment	HUMAN OTC DRUG LABEL	1	0363-2798	SOLUTION	3 g	TOPICAL	ANDA	16 sections
hair regrowth treatment	HUMAN OTC DRUG LABEL	1	0363-7202	SOLUTION	2 g	TOPICAL	ANDA	16 sections
Minoxidil (For Men)	HUMAN OTC DRUG LABEL	1	0363-9090	AEROSOL, FOAM	50 mg	TOPICAL	ANDA	16 sections
Minoxidil (For Women)	HUMAN OTC DRUG LABEL	1	0363-9091	AEROSOL, FOAM	50 mg	TOPICAL	ANDA	16 sections
Minoxidil	HUMAN OTC DRUG LABEL	1	0363-9970	SOLUTION	2 g	TOPICAL	ANDA	15 sections
Minoxidil	HUMAN OTC DRUG LABEL	1	0363-9971	SOLUTION	50 mg	TOPICAL	ANDA	16 sections
Minoxidil	HUMAN OTC DRUG LABEL	1	0363-9972	SOLUTION	2 g	TOPICAL	ANDA	15 sections
Minoxidil	HUMAN OTC DRUG LABEL	1	0363-9972	SOLUTION	2 g	TOPICAL	ANDA	15 sections
Minoxidil	HUMAN OTC DRUG LABEL	1	0363-9973	SOLUTION	50 mg	TOPICAL	ANDA	16 sections
Minoxidil	HUMAN OTC DRUG LABEL	1	0363-9973	SOLUTION	50 mg	TOPICAL	ANDA	16 sections
MinoxidilRegular Strength for Men	HUMAN OTC DRUG LABEL	1	0472-0066	SOLUTION	2 g	TOPICAL	ANDA	15 sections